[Determination of anti-Xa activity in cancer patients].
Low molecular-weight heparins (clexan, fraxiparin, fragmin) were used in cancer patients to prevent hemostatic system disorders and related complications. The adequacy and safety of therapy were assessed measuring plasma anti-Xa activity in 239 patients. When the prophylactic doses of the low molecular-weight heparins clexan, fraxiparin, and fragmin were given, their anticoagulative effect was similar as judged from anti-Xa activity. Clexan exhibited the maximum anti-Xa activity when the therapeutic doses of the low molecular-weight heparins were used.
Somonova
O V
OV
Madzhuga
A V
AV
Elizarova
A L
AL
Zubrikhina
G N
GN
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D017985:Dalteparin / Q000009:adverse effects / Q000627:therapeutic use; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use; D065427:Factor Xa Inhibitors; D006801:Humans; D017762:Nadroparin / Q000009:adverse effects / Q000627:therapeutic use; D009369:Neoplasms / Q000097:blood* / Q000150:complications / Q000628:therapy; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D017762:Nadroparin; D017985:Dalteparin